文献速递消化与肝胆胰病理细胞病理与分子病理

世界卫生组织胰胆管细胞病理报告系统诊断分类的恶性风险与总生存分析

Risk of malignancy and overall survival associated with the diagnostic categories in the World Health Organization Reporting System for Pancreaticobiliary Cytopathology.
PubMed 文献 · Cancer Cytopathol · 2024-06-30

该研究回顾性分析了1012例胰腺内镜超声引导下细针穿刺(EUS-FNA)样本,比较世界卫生组织(WHO)与Papanicolaou细胞病理学会(PSC)报告系统的恶性风险(ROM)和总生存。WHO系统通过新增PaN-Low和PaN-High分类并调整低级别恶性肿瘤归属,显著改善了ROM和总生存的分层。

要点

  • WHO系统各分类ROM:不足/不满意/无诊断8.3%,良性/阴性3.2%,非典型24.6%,PaN-Low 9.1%,PaN-High 46.7%,可疑恶性75%,恶性100%。
  • WHO系统对总生存的分层优于PSC系统。
  • WHO系统新增PaN-Low和PaN-High分类,并将低级别恶性肿瘤归入恶性类别。

核心结论

  • WHO系统通过引入PaN-Low和PaN-High分类并重新分配低级别恶性肿瘤,显著改善了各诊断分类的ROM和总生存分层。

研究设计与样本

  • 回顾性机构病理数据库检索,纳入2015年1月至2022年4月因胰腺病变行EUS-FNA的患者,共1012例样本重新分类。

主要发现

  • WHO系统ROM:不足/不满意/无诊断8.3%,良性/阴性3.2%,非典型24.6%,PaN-Low 9.1%,PaN-High 46.7%,可疑恶性75%,恶性100%。
  • PSC系统ROM:无诊断7.4%,阴性3.0%,非典型23.1%,肿瘤性良性0%,肿瘤性其他7.3%,可疑恶性75%,恶性100%。
  • WHO系统对总生存的分层优于PSC系统。

关键数值与推荐

  • WHO系统分类:不足/不满意/无诊断、良性/阴性、非典型、PaN-Low、PaN-High、可疑恶性、恶性。
  • PSC系统分类:无诊断、阴性、非典型、肿瘤性良性、肿瘤性其他、可疑恶性、恶性。

临床怎么用

  • 采用WHO系统分析EUS-FNA样本可为临床管理提供关键指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) classification system revised the Papanicolaou Society of Cytopathology (PSC) system for reporting pancreaticobiliary cytopathology. To better stratify intraductal and/or cystic neoplasms by cytologic grade, the neoplastic, other category was replaced by two new categories: pancreaticobiliary neoplasm, low-risk/grade (PaN-Low) and pancreaticobiliary neoplasm, high-risk/grade (PaN-High). Low-grade malignancies were placed in the malignant category, and benign neoplasms were placed in the benign/negative for malignancy category. METHODS: An institutional pathology database search identified patients who underwent endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for pancreatic lesions from January 2015 to April 2022. The absolute risk of malignancy (ROM) was determined by histologic and/or clinical follow-up of at least 6 months, and overall survival rates were calculated across diagnostic categories, comparing the WHO and PSC systems. RESULTS: In total, 1012 cases were reviewed and recategorized. The ROM for the WHO system was 8.3% for insufficient/inadequate/nondiagnostic, 3.2% for benign/negative for malignancy, 24.6% for atypical, 9.1% for PaN-Low, 46.7% for PaN-High, 75% for suspicious for malignancy, and 100% for malignant. Comparatively, the ROM for the PSC system was 7.4% for nondiagnostic, 3.0% for negative for malignancy, 23.1% for atypical, 0% for neoplastic, benign, 7.3% for neoplastic, other, 75% for suspicious for malignancy, and 100% for malignant. The WHO system demonstrated superior stratification for overall survival. CONCLUSIONS: The WHO system significantly improves the stratification of ROM and overall survival across diagnostic categories by introducing the PaN-Low and PaN-High categories and reassigning low-grade malignancies to the malignant category. Analyzing EUS-FNA samples with the WHO system provides critical insights for guiding clinical management.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hsiao WY, Wang Q. Risk of malignancy and overall survival associated with the diagnostic categories in the World Health Organization Reporting System for Pancreaticobiliary Cytopathology. Cancer Cytopathol. 2024. PMID: 38944695. doi:10.1002/cncy.22880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。